Foresee Business Summary

Foresee Pharmaceuticals (6576.TWO) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of licensing agreements, milestone payments, and tiered royalties derived from its proprietary drug delivery platforms. The company operates through two primary business segments: its Stabilized Injectable Formulation (SIF) platform, which produces long-acting injectables (LAI) such as the FDA-approved CAMCEVI® for advanced prostate cancer, and its New Chemical Entity (NCE) program targeting rare and inflammatory diseases. As of early 2026, Foresee has streamlined its operations by offloading its MMP-12 inhibitor portfolio to Primevera Therapeutics for up to $584.5 million to focus on the global commercial expansion of CAMCEVI and the late-stage development of FP-001 for central precocious puberty. In the competitive landscape, Foresee contends with local peers like PharmaEngine and Oneness Biotech, as well as global incumbents such as Tolmar (Eligard) and AbbVie (Lupron Depot), positioning itself as a high-value specialty player leveraging superior injection-ready formulations to capture market share from traditional multi-step depot systems. The company was founded by Chairman and CEO Dr. Benjamin Chien, a veteran entrepreneur who previously founded QPS Holdings, a leading global CRO. The leadership team includes Co-founder and CTO Dr. Yuhua Li, an expert in controlled-release technologies, and Chief Business Officer Dr. Mathieu Boudreau, who oversees strategic partnerships and licensing. Other key executives include CFO Max Chan, who manages the firm’s capital strategy on the Taipei Exchange, and CMO Dr. Yisheng Lee, who brings over 30 years of clinical research experience from institutions like Harvard and Stanford. Foresee is backed by a seasoned board of directors and a Scientific Advisory Board featuring prominent figures such as Dr. Daria Mochly-Rosen and Dr. Joseph Vacca, maintaining a strong institutional pedigree rooted in its spin-off origins from QPS.